🔬Deep Research
VIR — Vir Biotechnology · catalysts, narrative & risks
Context and reliability note
Vir Biotechnology (Nasdaq: VIR) is a clinical-stage biopharmaceutical company focused on infectious disease and cancer, operating two technology platforms — a next-generation antibody platform and the PRO-XTEN® protease-releasable masking technology [7], [23]. All figures below are drawn from the provided sources; where sources disagree, I flag the inconsistency rather than reconcile it. As of 2026-10-27 the stock trades around $11.57 with a market capitalization near $1.96B–$2.0B [9], [10], [11]. None of the following is investment advice.
Recent catalysts (roughly July–October 2026)
AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →